Anthracyclines and human epidermal growth factor 2 (HER2) inhibitors are primarily linked to heart failure (HF) and cardiac dysfunction; vascular endothelial growth factor (VEGF) inhibitors, mechanistic target of rapamycin (mTOR) inhibitors, and platinum-based therapies to arterial hypertension and venous thrombosis; checkpoint inhibitors to a variety of clinical effects, including vascular, myocardial, and pericardial disease [10]. Here, VEGFA is linked to heart failure.